In	in	O	O	O	O
vivo	vivo	O	O	O	O
characterization	characterization	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
dual	dual	O	O	O	O
adenosine	adenosine	CHEMICALS	O	OTHERS	I
A2A/A1	a2a/a1	O	O	O	O
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
in	in	O	O	O	O
animal	animal	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
in	in	O	O	O	O
vivo	vivo	O	O	O	O
characterization	characterization	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
dual	dual	O	O	O	O
adenosine	adenosine	CHEMICALS	O	OTHERS	I
A(2A)/A(1	a(2a)/a(1	O	O	OTHERS	I
)	)	O	O	OTHERS	I
receptor	receptor	O	O	OTHERS	I
antagonist	antagonist	O	O	OTHERS	I
in	in	O	O	O	O
several	several	O	O	O	O
animal	animal	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
is	is	O	O	O	O
described	described	O	O	O	O
.	.	O	O	O	O

Discovery	discovery	O	O	O	O
and	and	O	O	O	O
scale-up	scale-up	O	O	O	O
syntheses	syntheses	O	O	O	O
of	of	O	O	O	O
compound	compound	O	O	O	O
1	1	O	O	O	O
are	are	O	O	O	O
described	described	O	O	O	O
in	in	O	O	O	O
detail	detail	O	O	O	O
,	,	O	O	O	O
highlighting	highlighting	O	O	O	O
optimization	optimization	O	O	O	O
steps	steps	O	O	O	O
that	that	O	O	O	O
increased	increased	O	O	O	O
the	the	O	O	O	O
overall	overall	O	O	O	O
yield	yield	O	O	O	O
of	of	O	O	O	O
1	1	O	O	O	O
from	from	O	O	O	O
10.0	10.0	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
30.5	30.5	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Compound	compound	O	O	O	O
1	1	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
potent	potent	O	O	O	O
A(2A)/A(1	a(2a)/a(1	O	O	O	O
)	)	O	O	O	O
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
in	in	O	O	O	O
vitro	vitro	O	O	O	O
(	(	O	O	O	O
A(2A	a(2a	O	O	O	O
)	)	O	O	O	O
K(i	k(i	O	O	O	O
)	)	O	O	O	O
=	=	O	O	O	O
4.1	4.1	O	O	O	O
nM	nm	O	O	O	O
;	;	O	O	O	O
A(1	a(1	O	O	O	O
)	)	O	O	O	O
K(i	k(i	O	O	O	O
)	)	O	O	O	O
=	=	O	O	O	O
17.0	17.0	O	O	O	O
nM	nm	O	O	O	O
)	)	O	O	O	O
that	that	O	O	O	O
has	has	O	O	O	O
excellent	excellent	O	O	O	O
activity	activity	O	O	O	O
,	,	O	O	O	O
after	after	O	O	O	O
oral	oral	O	O	O	O
administration	administration	O	O	O	O
,	,	O	O	O	O
across	across	O	O	O	O
a	a	O	O	O	O
number	number	O	O	O	O
of	of	O	O	O	O
animal	animal	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
including	including	O	O	O	O
mouse	mouse	O	O	O	O
and	and	O	O	O	O
rat	rat	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
haloperidol-induced	haloperidol-induced	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
,	,	O	O	O	O
mouse	mouse	O	O	O	O
model	model	O	O	O	O
of	of	O	O	O	O
reserpine-induced	reserpine-induced	O	O	O	O
akinesia	akinesia	O	O	OTHERS	I
,	,	O	O	O	O
rat	rat	O	O	O	O
6-hydroxydopamine	6-hydroxydopamine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
6-OHDA	6-ohda	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
lesion	lesion	O	O	O	O
model	model	O	O	O	O
of	of	O	O	O	O
drug-induced	drug-induced	O	O	O	O
rotation	rotation	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
MPTP-treated	mptp-treated	O	O	O	O
non-human	non-human	O	O	O	O
primate	primate	O	O	O	O
model	model	O	O	O	O
.	.	O	O	O	O

